- Acova injection
- Acova uses
- Acova used to treat
- Acova acova drug
- Acova drug
- Acova pediatric dose
- Acova dosage
How is Acova (argatroban)given?
Argatroban is injected into a vein through an IV. You will receive this injection in a clinic or hospital setting. Argatroban is sometimes given together with aspirin.
If you are receiving this injection during an angioplasty procedure, the medicine will be given throughout the entire procedure and for up to 24 hours after the procedure.
Argatroban is given around the clock until your blood coagulates properly. Your doctor will test your blood often to determine how long to treat you with argatroban.
To be sure this medicine is helping your condition and is not causing harmful effects, your blood will need to be tested often. Visit your doctor regularly.
Because argatroban keeps your blood from coagulating (clotting) to prevent unwanted blood clots, it can also make it easier for you to bleed, even from a minor injury. Contact your doctor or seek emergency medical attention if you have bleeding that will not stop.
What should I avoid while receiving Acova (argatroban)?
Avoid activities that may increase your risk of bleeding or injury. Use extra care to prevent bleeding while shaving or brushing your teeth.
Avoid drinking alcohol. It may increase your risk of bleeding in your stomach or intestines.
Uses of Acova
Acova is a prescription medication used to treat or prevent a blood clot in patients with a specific condition called heparin-induced thrombocytopenia (HIT). HIT is a complication of treatment with a blood thinner called heparin that puts patients at a high risk for a blood clot.
Acova is also used to prevent blood clots in adult patients with or at risk for HIT who are undergoing a percutaneous coronary intervention (PCI), which is a procedure to open up narrowed or blocked blood vessels that supply blood to the heart.
This medication may be prescribed for other uses. Ask your doctor or pharmacist for more information.
Acova Drug Class
Acova is part of the drug class:
Direct thrombin inhibitors
Usual Pediatric Dose for Thrombotic/Thromboembolic Disorder
Infants and Children 16 years or younger: The safety and effectiveness of argatroban, including the appropriate anticoagulation goals and duration of therapy, have not been established among pediatric patients.
Note: Limited data available; dosing regimens not established. Titration of maintenance dose must consider multiple factors including current argatroban dose, current aPTT, target aPTT, and clinical status of the patient. For specific uses, required maintenance dose is highly variable between patients. Additionally, during the course of treatment, patient's dosing requirements may change as clinical status changes (e.g., sicker patients require lower dose); frequent dosage adjustments may be required to maintain desired anticoagulant activity. If argatroban therapy is used concurrently with or following FFP or a thrombolytic, some centers decrease dose by half.
Initial dose: 0.75 mcg/kg/minute by continuous IV infusion
Maintenance dose: Measure aPTT after 2 hours; adjust dose until the steady-state aPTT is 1.5 to 3 times the initial baseline value, not exceeding 100 seconds; adjust in increments of 0.1 to 0.25 mcg/kg/minute for normal hepatic function; reduce dose in hepatic impairment (see liver dose adjustment).
Note: A lower initial infusion rate may be needed in other pediatric patients with reduced clearance of argatroban (e.g., patients with heart failure, multiple organ system failure, severe anasarca, or postcardiac surgery). This precaution is based on adult studies of patients with these disease states who had reduced argatroban clearance.
No adjustment recommended